Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
Respiratory syncytial virus (RSV) is an established cause of serious lower respiratory disease in infants, elderly and high-risk populations. The OUTSMART surveillance program aims to characterize patient populations and currently circulating RSV strains, and monitor temporal and geographic evolutio...
Saved in:
Published in | PloS one Vol. 13; no. 7; p. e0200319 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
24.07.2018
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Respiratory syncytial virus (RSV) is an established cause of serious lower respiratory disease in infants, elderly and high-risk populations. The OUTSMART surveillance program aims to characterize patient populations and currently circulating RSV strains, and monitor temporal and geographic evolution of RSV F and G proteins in the U.S.
The OUTSMART 2016-17 study collected RSV-positive samples from 25 RSVAlert® laboratories from 4 U.S. regions and Puerto Rico during November 2016 through March 2017. Frequencies of A and B subtypes and genotypes were determined for several demographic and geographic variables. To gauge the representativeness of the OUTSMART patients, results were compared to discharge data from the NEDS and NIS databases.
A total of 1,041 RSV-positive samples with associated demographic data were obtained and the RSV F gene and second variable region of the G gene were sequenced. The majority of samples (76.0%) came from children under 2 years old: <1 year (48.4%), 1-2 years (27.6%). The OUTSMART patient sample was similar to NEDS and NIS for age, gender, and geographic location. Both OUTSMART and national RSV cases peaked in January. Of OUTSMART samples, 45.3% were subtype A, 53.7% were subtype B and 1.0% were mixed A and B. The percentage of RSV B cases increased with increasing age. Hospitalization (length of hospital stay, LOS, >24 hrs) occurred in 29.0% of patients of which 52.0% had RSV B. Outpatients (LOS <24 hrs) were 64.4% of total of which 73.3% were diagnosed in the ER and discharged, while only 6% were diagnosed in other outpatient settings.
The OUTSMART 2016-17 study was representative of the U.S. RSV experience. Geographic and temporal information from the RSV surveillance program will be used to establish a molecular baseline of RSV F and G sequence variability and to help inform development of novel agents for RSV prophylaxis and treatment. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: This work was sponsored by AstraZeneca/MedImmune. AR, AT, BL, YQ, HL, HJ, LY, JH, TV, and ME are employees and stockholders of AstraZeneca/MedImmune. SP, EL-S, XJ, and JF are employees of EpidStat Institute, which is a research institute that provides expert assistance on the evaluation of complex health issues and on the conduct and interpretation of epidemiological studies to pharmaceutical and medical device companies, and are paid consultants to AstraZeneca. ME, AR, HL, and LY (AstraZeneca/MedImmune) conceptualized the study design and set up data collection. XJ, SP, EL-S, JF, ME, AR, BL, YQ, HL, AT, HJ, JH, and TV made contributions to the analysis and interpretation of the data (AstraZeneca/MedImmune and EpidStat). SP, EL-S, ME, AR, and TV (AstraZeneca/MedImmune and EpidStat) drafted the manuscript and, along with BL, HJ, YQ, JH, (AstraZeneca/MedImmune) critically revised the manuscript. ME, AR, LY, TV, AT, SP, EL-S, and JF (AstraZeneca/MedImmune and EpidStat) were active participants in discussions regarding the development of the manuscript and decision to publish. This does not alter our adherence to PLOS ONE policies on sharing data and materials. AstraZeneca/Medimmune and Epidstat had no direct roles in study design, data collection, analysis, manuscript development or revision. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0200319 |